Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Pulmonary Circulation
|
July 24, 2018
Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension
Aditya A Joshi, Ryan Davey, Youlan Rao, et al.
BMC Health Services Research
|
May 6, 2019
Study protocol to investigate the efficacy of normalisation of Advance Care Planning (ACP) for people with chronic diseases in acute and community settings: a quasi-experimental design
Sarah Jeong, Tomiko Barrett, Se Ok Ohr, et al.
CJC Open
|
June 30, 2025
Barriers and Experiences in Implementing Early Hospital Discharge for Patients with Low-Risk ST-Elevation Myocardial Infarction
Vinay Jayachandiran, Elnaz Assadpour, Sofia Babapulle, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 27, 2025
SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II Trial
Constanza Vargas, Joe Carrello, Mathias Bressel, et al.
The Lancet. Oncology
|
May 17, 2026
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
Shankar Siva, Muhammad Ali, Nicholas Hardcastle, et al.
The Canadian Journal of Cardiology
|
March 9, 2020
Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care
Sharon Chih, Michael McDonald, Anne Dipchand, et al.
The Lancet. Oncology
|
February 29, 2024
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial
Shankar Siva, Mathias Bressel, Mark Sidhom, et al.
The Lancet. Oncology
|
May 17, 2026
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
Shankar Siva, David Pryor, Jarad Martin, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Pulmonary Circulation
|
July 24, 2018
Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension
Aditya A Joshi, Ryan Davey, Youlan Rao, et al.
BMC Health Services Research
|
May 6, 2019
Study protocol to investigate the efficacy of normalisation of Advance Care Planning (ACP) for people with chronic diseases in acute and community settings: a quasi-experimental design
Sarah Jeong, Tomiko Barrett, Se Ok Ohr, et al.
CJC Open
|
June 30, 2025
Barriers and Experiences in Implementing Early Hospital Discharge for Patients with Low-Risk ST-Elevation Myocardial Infarction
Vinay Jayachandiran, Elnaz Assadpour, Sofia Babapulle, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 27, 2025
SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II Trial
Constanza Vargas, Joe Carrello, Mathias Bressel, et al.
The Lancet. Oncology
|
May 17, 2026
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
Shankar Siva, Muhammad Ali, Nicholas Hardcastle, et al.
The Canadian Journal of Cardiology
|
March 9, 2020
Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care
Sharon Chih, Michael McDonald, Anne Dipchand, et al.
The Lancet. Oncology
|
February 29, 2024
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial
Shankar Siva, Mathias Bressel, Mark Sidhom, et al.
The Lancet. Oncology
|
May 17, 2026
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
Shankar Siva, David Pryor, Jarad Martin, et al.
Page
of 2